An Introduction to Edgewise Therapeutics

In this Industry Updates Webinar for the community, presented on March 18, 2021, attendees will learn about Edgewise, a clinical stage company launched in 2017. From Edgewise, “Our vision is to improve the lives of patients and families suffering from rare muscle disorders. Our approach is novel and potentially complementary with current approaches by directly targeting key muscle modulators. Our lead program, EDG-5506, is focused on Becker and Duchenne muscular dystrophies. We have successfully initiated Phase 1 healthy volunteer studies and plan to initiate studies in individuals with Becker in 2021." This Industry Update Webinar is sponsored by Edgewise Therapeutics. MDA is providing this resource as an educational opportunity for the neuromuscular disease community. This program is not sponsored, endorsed, or accredited by MDA.